Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CARLSMED, INC.CARL · Entity 5551 | 10% owner | July 24, 2025 | September 15, 2026 |
| Heartflow, Inc.HTFL · Entity 3993 | Director | June 16, 2026 | June 18, 2026 |
| Inspire Medical Systems, Inc.INSP · Entity 1186 | Director | July 15, 2026 | July 18, 2026 |
| Intersect ENT, Inc.XENT · Entity 127294 | Director | June 01, 2017 | June 05, 2017 |
| Mobia Medical, Inc.MOBI · Entity 5669 | Director | August 18, 2026 | August 21, 2026 |
| SHOULDER INNOVATIONS, INC.SI · Entity 5607 | Director · 10% owner | October 05, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CARLSMED, INC.
Report date July 24, 2025 · Filed September 15, 2026 · Amendment
Jointly reported with Presidio Management Group XII, L.L.C., U.S. Venture Partners XII, L.P.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 200,000 |
Reported balance
After 2025-07-24 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-07-24 · Purchase · Acquired 200,000 · Balance 200,000 F1: Stock held by Casey M. Tansey. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock held by Casey M. Tansey.
Heartflow, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $32.05 · Expires 2036-06-16 | Direct | 16,075 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 16,075 · Balance 16,075 F1: The option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to continued service through such date.
Inspire Medical Systems, Inc.
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,632 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 346 · Balance 26,632 F1: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 500 |
Reported balance
Holding disclosure · report date 2026-07-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 500 F2: Securities held by The Kimberly Tansey Irrevocable Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 500 |
Reported balance
Holding disclosure · report date 2026-07-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 500 F3: Securities held by The Kylie Tansey Irrevocable Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy.
F2: Securities held by The Kimberly Tansey Irrevocable Trust.
F3: Securities held by The Kylie Tansey Irrevocable Trust.
Intersect ENT, Inc.
Report date June 01, 2017 · Filed June 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,546 |
Reported balance
After 2017-06-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-06-01 · Grant · Acquired 2,546 · Balance 2,546 F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 1, 2018. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.05 · Expires 2027-05-31 | Direct | 6,035 |
Reported balance
After 2017-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-01 · Grant · Acquired 6,035 · Balance 6,035 F2: The shares subject to the option vest in 12 equal monthly installments commencing on June 1, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 1, 2018.
F2: The shares subject to the option vest in 12 equal monthly installments commencing on June 1, 2017.
Mobia Medical, Inc.
Report date August 18, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 318,332 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Purchase · Acquired 16,441 · Balance 318,332 F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.90 to $12.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.90 to $12.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
SHOULDER INNOVATIONS, INC.
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,445 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 733 · Balance 53,445 F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors. |
| Common StockSEC Table I · non-derivative | IndirectHeld by U.S. Venture Partners XII, L.P. | 1,686,403 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,686,403 F2: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P. ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), and U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A") and has sole voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. F3: Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Casey M. Tansey, a member of the Issuer's board of directors, is the managing partner of PMG Select and may be deemed to share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Each of the managing members and managing partner of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares. |
| Common StockSEC Table I · non-derivative | IndirectHeld by U.S. Venture Partners XII-A, L.P. | 85,586 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 85,586 F2: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P. ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), and U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A") and has sole voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. F3: Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Casey M. Tansey, a member of the Issuer's board of directors, is the managing partner of PMG Select and may be deemed to share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Each of the managing members and managing partner of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares. |
| Common StockSEC Table I · non-derivative | IndirectHeld by U.S. Venture Partners Select Fund I, L.P. | 921,130 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 921,130 F2: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P. ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), and U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A") and has sole voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. F3: Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Casey M. Tansey, a member of the Issuer's board of directors, is the managing partner of PMG Select and may be deemed to share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Each of the managing members and managing partner of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors.
F2: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P. ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), and U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A") and has sole voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A.
F3: Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Casey M. Tansey, a member of the Issuer's board of directors, is the managing partner of PMG Select and may be deemed to share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Each of the managing members and managing partner of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares.
Past disclosures · reporting ended (6)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARS Pharmaceuticals, Inc.
Report date December 08, 2020 · Filed December 09, 2020
Jointly reported with Presidio Management Group XII, L.L.C., U.S. Venture Partners XII, L.P., U.S. Venture Partners XII-A, L.P.
Section 16 reporting ended · disclosed 2020-12-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy U.S. Venture Partners XII, L.P. | 2,069,167 |
Last balance in matching sequence
After 2020-12-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-12-08 · Conversion · Acquired 1,779,969 · Balance 1,779,969 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 2 · 2020-12-08 · Conversion · Acquired 289,198 · Balance 2,069,167 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy U.S. Venture Partners XII-A, L.P. | 105,012 |
Last balance in matching sequence
After 2020-12-08 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 3 · 2020-12-08 · Conversion · Acquired 90,335 · Balance 90,335 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 4 · 2020-12-08 · Conversion · Acquired 14,677 · Balance 105,012 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Tansey | 47,619 |
Reported balance
After 2020-12-08 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2020-12-08 · Purchase · Acquired 47,619 · Balance 47,619 F1: The shares were purchased in the Issuer's initial public offering. |
| Preferred Series B StockSEC Table II · derivative / convertible security | IndirectBy U.S. Venture Partners XII, L.P. | 0 |
Reported balance
After 2020-12-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-12-08 · Conversion · Disposed 6,609,027 · Balance 0 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Preferred Series B StockSEC Table II · derivative / convertible security | IndirectBy U.S. Venture Partners XII-A, L.P. | 0 |
Reported balance
After 2020-12-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-12-08 · Conversion · Disposed 335,417 · Balance 0 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Preferred Series C StockSEC Table II · derivative / convertible security | IndirectBy U.S. Venture Partners XII, L.P. | 0 |
Reported balance
After 2020-12-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-12-08 · Conversion · Disposed 1,073,793 · Balance 0 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Preferred Series C StockSEC Table II · derivative / convertible security | IndirectBy U.S. Venture Partners XII-A, L.P. | 0 |
Reported balance
After 2020-12-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-12-08 · Conversion · Disposed 54,496 · Balance 0 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were purchased in the Issuer's initial public offering.
F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.
F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
BOX INC
Report date June 02, 2017 · Filed June 08, 2017 · Amendment
Jointly reported with Presidio Management Group IX, L.L.C., U S Venture Partners IX L P, FEDERMAN IRWIN, LIDDLE DAVID E, Matteucci Paul A, ROOT JONATHAN D, YOUNG PHILIP M
Section 16 reporting ended · disclosed 2017-06-08. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectDirectly owned by USVP IX | 0 |
Last balance in matching sequence
After 2017-06-02 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-06-02 · Conversion · Acquired 8,000,000 · Balance 8,000,000 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 2 · 2017-06-02 · Other · Disposed 8,000,000 · Balance 0 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2: Prorata distribution in kind from the partnership without consideration to its limited partners. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectDirectly owned by USVP IX | 3,713,775 |
Reported balance
After 2017-06-02 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2017-06-02 · Conversion · Disposed 8,000,000 · Balance 3,713,775 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F2: Prorata distribution in kind from the partnership without consideration to its limited partners.
F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
INTERMOLECULAR INC
Report date November 08, 2018 · Filed November 13, 2018
Jointly reported with Presidio Management Group IX, L.L.C., U S Venture Partners IX L P, KRAUSZ STEVEN M, LIDDLE DAVID E, Matteucci Paul A, ROOT JONATHAN D, YOUNG PHILIP M
Section 16 reporting ended · disclosed 2018-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by USVP IX | 0 |
Reported balance
After 2018-11-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-11-08 · Other · Disposed 4,280,779 · Balance 0 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | Direct | 856,155 |
Reported balance
After 2018-11-08 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-11-08 · Other · Acquired 856,155 · Balance 856,155 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-11-08 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-11-08 · Other · Disposed 856,155 · Balance 0 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Steven Krausz | 97,593 |
Last balance in matching sequence
After 2018-11-13 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 4 · 2018-11-08 · Other · Acquired 102,093 · Balance 102,093 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 5 · 2018-11-12 · Sale · Disposed 2,100 · Balance 99,993 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $.95 to $.96, inclusive for sales made on November 12, 2018. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 6 · 2018-11-13 · Sale · Disposed 2,400 · Balance 97,593 F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by David Liddle | 69,609 |
Reported balance
After 2018-11-08 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2018-11-08 · Other · Acquired 69,609 · Balance 69,609 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Paul Matteucci | 60,408 |
Reported balance
After 2018-11-08 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2018-11-08 · Other · Acquired 60,408 · Balance 60,408 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Jonathan Root | 85,851 |
Reported balance
After 2018-11-08 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2018-11-08 · Other · Acquired 85,851 · Balance 85,851 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Casey Tansey | 60,336 |
Reported balance
After 2018-11-08 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2018-11-08 · Other · Acquired 60,336 · Balance 60,336 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Philip Young | 82,370 |
Reported balance
After 2018-11-08 transaction · row 11
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 11 · 2018-11-08 · Other · Acquired 82,370 · Balance 82,370 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.
F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $.95 to $.96, inclusive for sales made on November 12, 2018. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Inari Medical, Inc.
Report date March 16, 2021 · Filed March 18, 2021
Jointly reported with Presidio Management Group X LLC, US VENTURE PARTNERS X LP, USVP X AFFILIATES LP
Section 16 reporting ended · disclosed 2021-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by USVP X | 2,619,872 |
Reported balance
After 2021-03-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-03-16 · Other · Disposed 2,619,872 · Balance 2,619,872 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by AFF X | 83,813 |
Reported balance
After 2021-03-16 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-03-16 · Other · Disposed 83,814 · Balance 83,813 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by PMG X. | 685,827 |
Reported balance
After 2021-03-16 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-03-16 · Other · Acquired 685,827 · Balance 685,827 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F3: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP Funds, without additional consideration. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by PMG X. | 0 |
Reported balance
After 2021-03-16 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-03-16 · Other · Disposed 685,827 · Balance 0 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F4: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration, to its members (the "PMG X Distribution"). Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Tansey | 242,988 |
Reported balance
After 2021-03-16 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-03-16 · Other · Acquired 77,296 · Balance 242,988 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.
F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
F3: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP Funds, without additional consideration. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
F4: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration, to its members (the "PMG X Distribution"). Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.
ON24 INC.
Report date August 17, 2021 · Filed August 19, 2021
Jointly reported with PRESIDIO MANAGEMENT GROUP VII L L C, US VENTURE PARTNERS VII L P, 2180 ASSOCIATES FUND VII L P, USVP ENTREPRENEUR PARTNERS VII A L P, USVP ENTREPRENEUR PARTNERS VII B L P
Section 16 reporting ended · disclosed 2021-08-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by USVP VII | 4,368,405 |
Reported balance
After 2021-08-17 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-08-17 · Other · Disposed 1,500,000 · Balance 4,368,405 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners VII, L.P. ("USVP VII") and 2180 Associates Fund VII, L.P. ("2180-VII'), without additional consideration to its partners or members. Presidio Management Group VII, L.L.C. ("PMG VII") received a pro-rata in-kind distribution from 2180-VII. F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by 2180-VII | 91,008 |
Reported balance
After 2021-08-17 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-08-17 · Other · Disposed 31,250 · Balance 91,008 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners VII, L.P. ("USVP VII") and 2180 Associates Fund VII, L.P. ("2180-VII'), without additional consideration to its partners or members. Presidio Management Group VII, L.L.C. ("PMG VII") received a pro-rata in-kind distribution from 2180-VII. F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein |
| Common StockSEC Table I · non-derivative | Direct | 312 |
Reported balance
After 2021-08-17 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-08-17 · Other · Acquired 312 · Balance 312 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners VII, L.P. ("USVP VII") and 2180 Associates Fund VII, L.P. ("2180-VII'), without additional consideration to its partners or members. Presidio Management Group VII, L.L.C. ("PMG VII") received a pro-rata in-kind distribution from 2180-VII. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-08-18 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-08-18 · Sale · Disposed 312 · Balance 0 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $20.50 inclusive for sales on 8/18/2021. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by EP7-A | 45,505 |
Reported balance
After 2021-08-18 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-08-18 · Sale · Disposed 15,625 · Balance 45,505 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $20.50 inclusive for sales on 8/18/2021. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by EP7-B | 45,505 |
Reported balance
After 2021-08-18 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2021-08-18 · Sale · Disposed 15,625 · Balance 45,505 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $20.50 inclusive for sales on 8/18/2021. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Casey Tansey | 5,000 |
Reported balance
Holding disclosure · report date 2021-08-17 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 5,000 F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners VII, L.P. ("USVP VII") and 2180 Associates Fund VII, L.P. ("2180-VII'), without additional consideration to its partners or members. Presidio Management Group VII, L.L.C. ("PMG VII") received a pro-rata in-kind distribution from 2180-VII.
F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $20.50 inclusive for sales on 8/18/2021. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
eFFECTOR Therapeutics, Inc.
Report date August 01, 2022 · Filed August 03, 2022
Jointly reported with Presidio Management Group X LLC, US VENTURE PARTNERS X LP, USVP X AFFILIATES LP, ROOT JONATHAN D
Section 16 reporting ended · disclosed 2022-08-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by USVP X | 3,981,940 |
Last balance in matching sequence
After 2022-08-03 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2022-08-01 · Sale · Disposed 25,896 · Balance 4,066,868 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 3 · 2022-08-02 · Sale · Disposed 27,348 · Balance 4,039,520 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 5 · 2022-08-03 · Sale · Disposed 57,580 · Balance 3,981,940 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by AFF X | 127,569 |
Last balance in matching sequence
After 2022-08-03 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2022-08-01 · Sale · Disposed 807 · Balance 130,218 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 4 · 2022-08-02 · Sale · Disposed 853 · Balance 129,365 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 6 · 2022-08-03 · Sale · Disposed 1,796 · Balance 127,569 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2025 Filed Aug 5, 2025 20:05 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | PurchaseCommon Stock | 40,000 | $15.00 | $600,000.00 |
DisclosureSEC source: 0001641172-25-022252 · ownership.xml · nonDerivative · entry 5 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,666 Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:05 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | GrantCommon Stock | 7,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-022252 · ownership.xml · nonDerivative · entry 4 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,666 F4 · shares: Represents an award of restricted stock units ("RSUs"). The RSUs will vest on the earlier of the date of the annual meeting of stockholders to be held in 2026 or August 1, 2026. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:05 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | ConversionCommon Stock | 921,131 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-022252 · ownership.xml · nonDerivative · entry 3 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By U.S. Venture Partners Select Fund I-A, L.P. Disclosed balance after: 921,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F2 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I-A, L.P. ("USVP Select") and has sole voting and dispositive power with respect to the shares held by USVP Select. F3 · ownership.nature: The Reporting Person, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP Select. Each of the managing members of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:05 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | ConversionCommon Stock | 85,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-022252 · ownership.xml · nonDerivative · entry 2 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By U.S. Venture Partners XII-A, L.P. Disclosed balance after: 85,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F2 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I-A, L.P. ("USVP Select") and has sole voting and dispositive power with respect to the shares held by USVP Select. F3 · ownership.nature: The Reporting Person, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP Select. Each of the managing members of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:05 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | ConversionCommon Stock | 1,686,403 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-022252 · ownership.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By U.S. Venture Partners XII, L.P. Disclosed balance after: 1,686,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F2 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I-A, L.P. ("USVP Select") and has sole voting and dispositive power with respect to the shares held by USVP Select. F3 · ownership.nature: The Reporting Person, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP Select. Each of the managing members of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares. Read SEC document |
| July 24, 2025 Filed Sep 15, 2026 21:07 UTC Amendment | CARLSMED, INC. CARL · Entity 5551 | PurchaseCommon Stock | 200,000 | $15.00 | $3,000,000.00 |
DisclosureSEC source: 0001193125-26-392111 · ownership.xml · nonDerivative · entry 1 Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 200,000 F1 · ownership.nature: Stock held by Casey M. Tansey. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:47 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionPreferred Series C Stock · Derivative | 1,117,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-020276 · form4-07252025_120712.xml · derivative · entry 14 Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,117,743 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F1 · derivative.exercise_date: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F1 · derivative.expiration_date: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F3 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"). Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and, together with USVP XII, USVP XII-A, U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"), and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. PMG XII and PMG SFI may be deemed to share voting and dispositive power over the stock held by USVP. F4 · ownership.nature: Each of Jonathan D. Root, Richard W. Lewis, Dafina Toncheva and Steven M. Krausz, are managing members of PMG XII, who may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein. F6 · ownership.nature: Stock held by USVP SFI, on its own behalf and as nominee for USVP SFI-A. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:47 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionPreferred Series C Stock · Derivative | 26,993 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-020276 · form4-07252025_120712.xml · derivative · entry 13 Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 26,993 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F1 · derivative.exercise_date: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F1 · derivative.expiration_date: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F3 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"). Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and, together with USVP XII, USVP XII-A, U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"), and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. PMG XII and PMG SFI may be deemed to share voting and dispositive power over the stock held by USVP. F4 · ownership.nature: Each of Jonathan D. Root, Richard W. Lewis, Dafina Toncheva and Steven M. Krausz, are managing members of PMG XII, who may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein. F5 · ownership.nature: Stock Held by USVP XII-A. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:47 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionPreferred Stock Series B · Derivative | 41,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-020276 · form4-07252025_120712.xml · derivative · entry 12 Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 41,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F1 · derivative.exercise_date: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F1 · derivative.expiration_date: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F3 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"). Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and, together with USVP XII, USVP XII-A, U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"), and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. PMG XII and PMG SFI may be deemed to share voting and dispositive power over the stock held by USVP. F4 · ownership.nature: Each of Jonathan D. Root, Richard W. Lewis, Dafina Toncheva and Steven M. Krausz, are managing members of PMG XII, who may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein. F5 · ownership.nature: Stock Held by USVP XII-A. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:47 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionPreferred Series A Stock · Derivative | 149,655 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-020276 · form4-07252025_120712.xml · derivative · entry 11 Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 149,655 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F1 · derivative.exercise_date: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F1 · derivative.expiration_date: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F3 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"). Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and, together with USVP XII, USVP XII-A, U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"), and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. PMG XII and PMG SFI may be deemed to share voting and dispositive power over the stock held by USVP. F4 · ownership.nature: Each of Jonathan D. Root, Richard W. Lewis, Dafina Toncheva and Steven M. Krausz, are managing members of PMG XII, who may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein. F5 · ownership.nature: Stock Held by USVP XII-A. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:47 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionPreferred Series C Stock · Derivative | 531,877 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-020276 · form4-07252025_120712.xml · derivative · entry 10 Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 531,877 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F1 · derivative.exercise_date: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F1 · derivative.expiration_date: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F2 · ownership.nature: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"). F3 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"). Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and, together with USVP XII, USVP XII-A, U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"), and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. PMG XII and PMG SFI may be deemed to share voting and dispositive power over the stock held by USVP. F4 · ownership.nature: Each of Jonathan D. Root, Richard W. Lewis, Dafina Toncheva and Steven M. Krausz, are managing members of PMG XII, who may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:47 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionPreferred Series B Stock · Derivative | 825,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-020276 · form4-07252025_120712.xml · derivative · entry 9 Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 825,135 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F1 · derivative.exercise_date: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F1 · derivative.expiration_date: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F2 · ownership.nature: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"). F3 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"). Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and, together with USVP XII, USVP XII-A, U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"), and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. PMG XII and PMG SFI may be deemed to share voting and dispositive power over the stock held by USVP. F4 · ownership.nature: Each of Jonathan D. Root, Richard W. Lewis, Dafina Toncheva and Steven M. Krausz, are managing members of PMG XII, who may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:47 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionPreferred Series A Stock · Derivative | 2,948,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-020276 · form4-07252025_120712.xml · derivative · entry 8 Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,948,794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F1 · derivative.exercise_date: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F1 · derivative.expiration_date: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F2 · ownership.nature: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"). F3 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"). Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and, together with USVP XII, USVP XII-A, U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"), and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. PMG XII and PMG SFI may be deemed to share voting and dispositive power over the stock held by USVP. F4 · ownership.nature: Each of Jonathan D. Root, Richard W. Lewis, Dafina Toncheva and Steven M. Krausz, are managing members of PMG XII, who may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:47 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionCommon Stock | 1,117,743 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-020276 · form4-07252025_120712.xml · nonDerivative · entry 7 Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,117,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F3 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"). Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and, together with USVP XII, USVP XII-A, U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"), and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. PMG XII and PMG SFI may be deemed to share voting and dispositive power over the stock held by USVP. F4 · ownership.nature: Each of Jonathan D. Root, Richard W. Lewis, Dafina Toncheva and Steven M. Krausz, are managing members of PMG XII, who may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein. F6 · ownership.nature: Stock held by USVP SFI, on its own behalf and as nominee for USVP SFI-A. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:47 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionCommon Stock | 26,993 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-020276 · form4-07252025_120712.xml · nonDerivative · entry 6 Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 218,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F3 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"). Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and, together with USVP XII, USVP XII-A, U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"), and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. PMG XII and PMG SFI may be deemed to share voting and dispositive power over the stock held by USVP. F4 · ownership.nature: Each of Jonathan D. Root, Richard W. Lewis, Dafina Toncheva and Steven M. Krausz, are managing members of PMG XII, who may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein. F5 · ownership.nature: Stock Held by USVP XII-A. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:47 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionCommon Stock | 41,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-020276 · form4-07252025_120712.xml · nonDerivative · entry 5 Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 191,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F3 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"). Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and, together with USVP XII, USVP XII-A, U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"), and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. PMG XII and PMG SFI may be deemed to share voting and dispositive power over the stock held by USVP. F4 · ownership.nature: Each of Jonathan D. Root, Richard W. Lewis, Dafina Toncheva and Steven M. Krausz, are managing members of PMG XII, who may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein. F5 · ownership.nature: Stock Held by USVP XII-A. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:47 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionCommon Stock | 149,655 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-020276 · form4-07252025_120712.xml · nonDerivative · entry 4 Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 149,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F3 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"). Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and, together with USVP XII, USVP XII-A, U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"), and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. PMG XII and PMG SFI may be deemed to share voting and dispositive power over the stock held by USVP. F4 · ownership.nature: Each of Jonathan D. Root, Richard W. Lewis, Dafina Toncheva and Steven M. Krausz, are managing members of PMG XII, who may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein. F5 · ownership.nature: Stock Held by USVP XII-A. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:47 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionCommon Stock | 531,877 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-020276 · form4-07252025_120712.xml · nonDerivative · entry 3 Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,305,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F2 · ownership.nature: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"). F3 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"). Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and, together with USVP XII, USVP XII-A, U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"), and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. PMG XII and PMG SFI may be deemed to share voting and dispositive power over the stock held by USVP. F4 · ownership.nature: Each of Jonathan D. Root, Richard W. Lewis, Dafina Toncheva and Steven M. Krausz, are managing members of PMG XII, who may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:47 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionCommon Stock | 825,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-020276 · form4-07252025_120712.xml · nonDerivative · entry 2 Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,773,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F2 · ownership.nature: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"). F3 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"). Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and, together with USVP XII, USVP XII-A, U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"), and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. PMG XII and PMG SFI may be deemed to share voting and dispositive power over the stock held by USVP. F4 · ownership.nature: Each of Jonathan D. Root, Richard W. Lewis, Dafina Toncheva and Steven M. Krausz, are managing members of PMG XII, who may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:47 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionCommon Stock | 2,948,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-020276 · form4-07252025_120712.xml · nonDerivative · entry 1 Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,948,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of preferred stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split"). Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted 1-to-1 basis with no additional consideration and have no expiration date. F2 · ownership.nature: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"). F3 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"). Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and, together with USVP XII, USVP XII-A, U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"), and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. PMG XII and PMG SFI may be deemed to share voting and dispositive power over the stock held by USVP. F4 · ownership.nature: Each of Jonathan D. Root, Richard W. Lewis, Dafina Toncheva and Steven M. Krausz, are managing members of PMG XII, who may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. Each such persons and entities disclaim beneficial ownership of the reported securities held by the USVP XII Funds, except to the extent of any pecuniary interest therein. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 20:07 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 133 | $128.00 | $17,024.00 |
DisclosureSEC source: 0001104659-25-068328 · tm2521079-3_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,014 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| May 01, 2025 Filed May 5, 2025 23:26 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 1,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-044669 · tm2514079-3_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,881 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest upon the earlier to occur of (a) the first anniversary of the date of grant or (b) the date that is immediately prior to the occurrence of a Change of Control (as defined in the Issuer's 2018 Incentive Award Plan), in each case subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 20:08 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 103 | $149.70 | $15,419.10 |
DisclosureSEC source: 0001104659-25-035499 · tm2512484-4_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,615 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 01:15 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 81 | $176.33 | $14,282.73 |
DisclosureSEC source: 0001104659-25-004600 · tm253739-1_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,512 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| October 14, 2024 Filed Oct 16, 2024 20:23 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 68 | $210.46 | $14,311.28 |
DisclosureSEC source: 0001104659-24-109201 · tm2426283-4_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,431 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:09 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 103 | $138.58 | $14,273.74 |
DisclosureSEC source: 0001104659-24-080587 · tm2419668-5_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,363 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| May 02, 2024 Filed May 6, 2024 22:23 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 716 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-057572 · tm2413647-7_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,260 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest upon the earlier to occur of (a) the first anniversary of the date of grant or (b) the date that is immediately prior to the occurrence of a Change of Control (as defined in the Issuer's 2018 Incentive Award Plan), in each case subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 21:17 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 62 | $231.74 | $14,367.88 |
DisclosureSEC source: 0001104659-24-047892 · tm2411955-4_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,544 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| January 16, 2024 Filed Jan 19, 2024 01:43 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 77 | $186.10 | $14,329.70 |
DisclosureSEC source: 0001104659-24-004906 · tm243653-1_4seq1.xml · nonDerivative · entry 7 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,482 F5 · shares: Represents shares of Common Stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| January 16, 2024 Filed Jan 19, 2024 01:43 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 8 | $150.47 | $1,203.76 |
DisclosureSEC source: 0001104659-24-004906 · tm243653-1_4seq1.xml · nonDerivative · entry 6 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,405 F4 · shares: Represents settlement of shares of Common Stock issued in lieu of cash fees to which the Reporting Person was previously granted pursuant to the Company's Non-Employee Director Compensation Policy in respect of compensation for the third quarter of 2023 and inadvertently not previously issued due to a clerical error. Read SEC document |
| January 16, 2024 Filed Jan 19, 2024 01:43 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 2 | $325.91 | $651.82 |
DisclosureSEC source: 0001104659-24-004906 · tm243653-1_4seq1.xml · nonDerivative · entry 5 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,397 F3 · shares: Represents settlement of shares of Common Stock issued in lieu of cash fees to which the Reporting Person was previously granted pursuant to the Company's Non-Employee Director Compensation Policy in respect of compensation for the second quarter of 2023 and inadvertently not previously issued due to a clerical error. Read SEC document |
| October 13, 2023 Filed Oct 17, 2023 23:49 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 87 | $150.47 | $13,090.89 |
DisclosureSEC source: 0001104659-23-109695 · tm2328548-4_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,395 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy Read SEC document |
| August 25, 2023 Filed Jan 19, 2024 01:43 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004906 · tm243653-1_4seq1.xml · nonDerivative · entry 4 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 500 F2 · ownership.nature: Securities held by The Kylie Tansey Irrevocable Trust. Read SEC document |
| August 25, 2023 Filed Jan 19, 2024 01:43 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004906 · tm243653-1_4seq1.xml · nonDerivative · entry 3 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 500 F1 · ownership.nature: Securities held by The Kimberly Tansey Irrevocable Trust. Read SEC document |
| August 25, 2023 Filed Jan 19, 2024 01:43 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004906 · tm243653-1_4seq1.xml · nonDerivative · entry 2 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,395 Read SEC document |
| August 25, 2023 Filed Jan 19, 2024 01:43 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004906 · tm243653-1_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,895 Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 20:52 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 40 | $325.91 | $13,036.40 |
DisclosureSEC source: 0001104659-23-082383 · tm2321602-7_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,308 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| April 27, 2023 Filed May 1, 2023 23:50 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 669 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-054648 · tm2314266-6_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,268 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest upon the earlier to occur of (a) the first anniversary of the date of grant or (b) the date that is immediately prior to the occurrence of a Change of Control (as defined in the Issuer's 2018 Incentive Award Plan), in each case subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 20:11 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 56 | $231.77 | $12,979.12 |
DisclosureSEC source: 0001104659-23-044585 · tm2312581-6_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,599 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| January 10, 2023 Filed Jan 20, 2023 00:53 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 52 | $248.31 | $12,912.12 |
DisclosureSEC source: 0001104659-23-005111 · tm233800-1_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,543 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| October 11, 2022 Filed Oct 13, 2022 20:19 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 81 | $168.98 | $13,687.38 |
DisclosureSEC source: 0001104659-22-108499 · tm2228171-2_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,491 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| August 03, 2022 Filed Aug 3, 2022 21:58 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 1,796 | $0.80 | $1,443.98 |
DisclosureSEC source: 0001062993-22-017215 · form4.xml · nonDerivative · entry 6 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 127,569 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| August 03, 2022 Filed Aug 3, 2022 21:58 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 57,580 | $0.80 | $46,294.32 |
DisclosureSEC source: 0001062993-22-017215 · form4.xml · nonDerivative · entry 5 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 3,981,940 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 21:58 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 853 | $0.80 | $679.84 |
DisclosureSEC source: 0001062993-22-017215 · form4.xml · nonDerivative · entry 4 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 129,365 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 21:58 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 27,348 | $0.80 | $21,796.36 |
DisclosureSEC source: 0001062993-22-017215 · form4.xml · nonDerivative · entry 3 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,039,520 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:58 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 807 | $0.79 | $634.30 |
DisclosureSEC source: 0001062993-22-017215 · form4.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 130,218 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:58 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 25,896 | $0.79 | $20,354.26 |
DisclosureSEC source: 0001062993-22-017215 · form4.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,066,868 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| July 28, 2022 Filed Jul 30, 2022 00:54 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 984 | $0.89 | $877.73 |
DisclosureSEC source: 0001062993-22-016924 · form4.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 131,025 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.89 to $0.91, inclusive for sales on 7/28/22. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| July 28, 2022 Filed Jul 30, 2022 00:54 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 31,533 | $0.89 | $28,127.44 |
DisclosureSEC source: 0001062993-22-016924 · form4.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,092,764 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.89 to $0.91, inclusive for sales on 7/28/22. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| July 27, 2022 Filed Jul 27, 2022 22:20 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 1,321 | $0.89 | $1,178.33 |
DisclosureSEC source: 0001062993-22-016802 · form4.xml · nonDerivative · entry 6 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 132,009 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.91 to $0.95, inclusive for sales on 7/25/22; prices ranging from $0.90 to $0.91, inclusive for sales on 7/26/22; and prices ranging from $0.89 to $0.91, inclusive for sales on 7/27/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.